NOV
vs
LLY
NOV
LLY
Over the past 12 months, NOV has underperformed LLY, delivering a return of -51% compared to the LLY's +32% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
NOV
LLY
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S
XMUN:NOV
|
40.44
EUR
|
|||||
|
Eli Lilly and Co
NYSE:LLY
|
1 110.15
USD
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
NOV, LLY
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Novo Nordisk A/S
Revenue
|
|||||||||||
|
Eli Lilly and Co
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
NOV, LLY
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Novo Nordisk A/S
XMUN:NOV
|
|||||||||
|
Eli Lilly and Co
NYSE:LLY
|
|||||||||
Compare company's free cash flow with its competitors.
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
NOV, LLY
Performance By Year
NOV, LLY
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.